BUTINI STEFANIA

Stefania
Butini
Professore Associato

Office hours

  • Friday from 11:30 to 12:30
    Place: Stanza 10167, Polo Scientifico S. Miniato, si prega di inviare e-mail per verificare la disponibilità. Per motivi di sicurzza il docente riceve presso l'aula virtuale del sito docente (https://docenti.unisi.it/it/butini) secondo le stesse modalità
  •  If didactic activities are scheduled on Friday at the indicated time (please check the lessons' timetable), you are kindly asked to contact the  teacher via e-mail
      

Teaching activities

Completion accademic year: 2022/2023

Course year: 4 Full cicle (5 years) PHARMACY A.Y. 2019/2020

Completion accademic year: 2021/2022

Course year: 4 Full cicle (5 years) PHARMACY A.Y. 2018/2019

Completion accademic year: 2020/2021

Course year: 4 Full cicle (5 years) PHARMACY A.Y. 2017/2018

Completion accademic year: 2019/2020

Course year: 3 Full cicle (5 years) PHARMACY A.Y. 2017/2018

Research

Prof Stefania Butini is associate professor of medicinal chemistry since 2015. She earned the degree of chemistry and pharmaceutical technology at the University of Siena in 1997 and a PhD in pharmaceutical sciences at the same University in 2000. In 1999-2000 she spent a period of internship at the University of Groningen under the supervision of Prof H.W. Wikström working on Parkinson Disease and the development of dopamine D3 receptor modulators. In 2004 she became permanent senior researcher at the University of Siena.

Her research activity focuses on the development of bioactive compounds with a special emphasis on CNS diseases, antimalarial, and antitumor agents. Exploration of chemistry and biology of synthetic organic molecules with therapeutic potential in neurodegenerative and neuropsychiatric diseases is a key part her research interests that include target selection, rational design of innovative drugs, discovery of new synthetic methodologies, and general strategies for synthesis, bioinformatics and the study of structure-function relationships. She is experienced as Research Units’ coordinator in National and International polycentric research projects dealing with drug development in various fields.

Ultime pubblicazioni:

  • Relitti, N., Prasanth Saraswati, A., Carullo, G., Papa, A., Monti, A., Benedetti, R., et al. (2022). Design and Synthesis of Oligopeptidic Parvulin Inhibitors. CHEMMEDCHEM, e202200050 [10.1002/cmdc.202200050]. - view more
  • Brogi, S., Rossi, S., Ibba, R., Butini, S., Calderone, V., Campiani, G., et al. (2022). In Silico Analysis of Peptide-Based Derivatives Containing Bifunctional Warheads Engaging Prime and Non-Prime Subsites to Covalent Binding SARS-CoV-2 Main Protease (Mpro). COMPUTATION, 10(5), 69 [10.3390/computation10050069]. - view more
  • Papa, A., Pasquini, S., Contri, C., Gemma, S., Campiani, G., Butini, S., et al. (2022). Polypharmacological approaches for CNS diseases: focus on endocannabinoid degradation inhibition. CELLS, 11(3), 1-38 [10.3390/cells11030471]. - view more
  • Brogi, S., Ibba, R., Rossi, S., Butini, S., Calderone, V., Gemma, S., et al. (2022). Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases. MOLECULES, 27(8), 2561 [10.3390/molecules27082561]. - view more
  • Bergantini, L., D'Alessandro, M., Gangi, S., Cavallaro, D., Campiani, G., Butini, S., et al. (2022). Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a New Protocol for Investigating the Mechanisms of Idiopathic Pulmonary Fibrosis. CELLS, 11(9), 1441 [10.3390/cells11091441]. - view more